Brief: Anavex Life Sciences Provides Update On Regulatory Review In The EU For Blarcamesine To Treat Early Alzheimer’S Disease
25/03/2026 11:53
Anavex Life Sciences Corp AVXL.O: ANAVEX LIFE SCIENCES PROVIDES UPDATE ON REGULATORY REVIEW IN THE EU FOR BLARCAMESINE TO TREAT EARLY ALZHEIMER’S DISEASE ANAVEX LIFE SCIENCES CORP - WITHDRAWS EU MARKETING AUTHORIZATION APPLICATION FOR BLARCAMESINE ANAVEX LIFE SCIENCES CORP - REMAINS COMMITTED TO CLINICAL DEVELOPMENT OF BLARCAMESINE FOR EARLY ALZHEIMER'S Source text: ID:nGNX1N76YV Further company coverage: AVXL.O
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board